Revolution Medicines' Rasonque Receives FDA Approval for Advanced Pancreatic Cancer
By Editor • August 26, 2026 • 1 min read
In a significant breakthrough for pancreatic cancer treatment, the U.S. Food and Drug Administration (FDA) has approved Rasonque, a new drug by Revolution Medicines, designed specifically for patients with advanced, metastatic cancer. This once-daily pill has been proven to double survival rates in a large clinical trial, providing fresh optimism for those who have exhausted other treatment options.
Rasonque targets various forms of the RAS protein, a key driver in tumor growth for many pancreatic cancer cases. The approval comes at a critical time, as the drug aims to support patients who have previously undergone treatment or are unable to receive combination chemotherapy. Priced at $39,800 for a 30-day supply, the company also plans to offer assistance programs to help with the costs.
The excitement surrounding Rasonque surged after trial results were announced in April, prompting the FDA to allow early access through its compassionate use program. Patients like Barbara Andes, 88, from California, have reported significant quality-of-life improvements since starting the drug, finding it a welcome change from the debilitating effects of chemotherapy.
Mark Goldsmith, CEO of Revolution, emphasized the importance of this approval, highlighting over a decade of dedicated research into pancreatic cancer. Following the news, Revolution's stock soared by 166% this year, reflecting investor confidence in Rasonque's potential market impact. Analysts predict the drug could generate substantial revenue, estimating third-quarter U.S. earnings to reach around $28 million, with projections of $148 million in the fourth quarter and an impressive $11.5 billion in annual global sales.
Experts believe Rasonque could transform treatment strategies for pancreatic cancer, which remains one of the most challenging forms of cancer to combat. As Dr. Rachna Shroff noted, this marks just the beginning of advancements in targeting the RAS pathway.
Source: www.france24.com
#FDA #pancreatic cancer #RAS protein #Rasonque #Revolution Medicines
